Sensorion, Novasep ink gene therapy agreement

By The Science Advisory Board staff writers

October 27, 2020 -- Sensorion and Novasep have signed an agreement for the manufacturing of adeno-associated virus (AAV) vectors covering a gene therapy program that targets OTOF, the gene encoding the otoferlin protein. Mutations of OTOF can lead to severe congenital hearing loss.

OTOF-GT, Sensorion's most advanced program, aims to restore the expression of otoferlin in the inner hair cells of the ear, where it plays an essential role in hearing.

Under the terms of the agreement, Novasep will be in charge of developing and manufacturing the two AAV vectors designed for Sensorion's OTOF-GT product and will supply drug product batches to support preclinical and clinical studies. Development and manufacturing activities include cell culture, AAV expression, purification, aseptic distribution, and quality control.

Bayer acquires Asklepios to advance gene therapies
Bayer has agreed to pay $2 billion to acquire Asklepios BioPharmaceutical, a U.S.-based biotechnology company specializing in gene therapies.
New methods could improve AAV quality for viral vector manufacturing
Developing well-characterized adeno-associated viral vectors (AAVs) is a significant obstacle for the biomanufacturing industry. A group of analytical...
Customized gene therapies successfully target rare eye diseases
Can gene therapies prove effective for the treatment of rare genetic diseases? One company may have found a solution that incorporates a high degree of...

Copyright © 2020 scienceboard.net


Register below for our weekly Letter from the Editor to receive the latest Science news and insights.
Email
Conferences
Festival of Genomics & Biodata
January 28-29, 2021
London, Greater London United Kingdom
Lab of the Future USA
May 11-12, 2021
Boston, Massachusetts United States
Connect
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter